Cummings MD, Sekharan S. Structure-based macrocycle design in small-molecule drug discovery and simple metrics to identify opportunities for macrocyclization of small-molecule ligands. J Med Chem. 2019;62:6843–53.

Article  CAS  PubMed  Google Scholar 

Diao Y, Liu D, Ge H, Zhang R, Jiang K, Bao R, et al. Macrocyclization of linear molecules by deep learning to facilitate macrocyclic drug candidates discovery. Nat Commun. 2023;14:4552.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Darlami O, Pun R, Ahn S-H, Kim S-H, Shin D. Macrocyclization strategy for improving candidate profiles in medicinal chemistry. Eur J Med Chem. 2024;272:116501.

Article  CAS  PubMed  Google Scholar 

Jimenez DGarcia, Poongavanam V, Kihlberg J. Macrocycles in drug discovery─ learning from the past for the future. J Med Chem. 2023;66:5377–96.

Article  Google Scholar 

Zhang C, Liu F, Zhang Y, Song C. Macrocycles and macrocyclization in anticancer drug discovery: important pieces of the puzzle. Eur J Med Chem. 2024;268:116234.

Article  CAS  PubMed  Google Scholar 

Li Y-H, Lin Y-K, Cai J-F, Zou Z-K, Zhao P-L. A perspective on the application of macrocyclic design strategies in antitumor drugs. Bioorg Chem. 2025;156:108190.

Article  CAS  PubMed  Google Scholar 

Kopp F, Stratton CF, Akella LB, Tan DS. A diversity-oriented synthesis approach to macrocycles via oxidative ring expansion. Nat Chem Biol. 2012;8:358–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mortensen KT, Osberger TJ, King TA, Sore HF, Spring DR. Strategies for the diversity-oriented synthesis of macrocycles. Chem Rev. 2019;119:10288–317.

Article  CAS  PubMed  Google Scholar 

Gao Y, Kodadek T. Direct comparison of linear and macrocyclic compound libraries as a source of protein ligands. ACS Combinatorial Sci. 2015;17:190–5.

Article  CAS  Google Scholar 

Ermert P. Design, properties and recent application of macrocycles in medicinal chemistry. Chimia (Aarau). 2017;71:678–678.

Article  CAS  PubMed  Google Scholar 

Amrhein JA, Knapp S, Hanke T. Synthetic opportunities and challenges for macrocyclic kinase inhibitors. J Med Chem. 2021;64:7991–8009.

Article  CAS  PubMed  Google Scholar 

Filippakopoulos P, Knapp S. The bromodomain interaction module. FEBS Lett. 2012;586:2692–704.

Article  CAS  PubMed  Google Scholar 

Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert J-P, Barsyte-Lovejoy D, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012;149:214–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trojer P. Targeting BET bromodomains in cancer. Annual Rev cancer Biol. 2022;6:313–36.

Article  Google Scholar 

Wang N, Wu R, Tang D, Kang R. The BET family in immunity and disease. Signal Transduct Target Ther. 2021;6:23.

Article  PubMed  PubMed Central  Google Scholar 

Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, Agno JE, et al. Small-molecule inhibition of BRDT for male contraception. Cell. 2012;150:673–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miller TC, Simon B, Rybin V, Grötsch H, Curtet S, Khochbin S, et al. A bromodomain–DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT. Nat Commun. 2016;7:13855.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Philpott M, Rogers CM, Yapp C, Wells C, Lambert J-P, Strain-Damerell C, et al. Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching. Epigenetics Chromatin. 2014;7:14.

Article  PubMed  PubMed Central  Google Scholar 

Tyler DS, Vappiani J, Cañeque T, Lam EY, Ward A, Gilan O, et al. Click chemistry enables preclinical evaluation of targeted epigenetic therapies. Science. 2017;356:1397–401.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andrieu G, Belkina AC, Denis GV. Clinical trials for BET inhibitors run ahead of the science. Drug Discov Today: Technol. 2016;19:45–50.

Article  PubMed  Google Scholar 

Piha-Paul SA, Hann CL, French CA, Cousin S, Braña I, Cassier PA, et al. Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors. JNCI Cancer Spectr. 2020;4:pkz093.

Article  PubMed  Google Scholar 

Moreno V, Sepulveda J, Vieito M, Hernández-Guerrero T, Doger B, Saavedra O, et al. Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin’s lymphoma. Ann Oncol. 2020;31:780–8.

Article  CAS  PubMed  Google Scholar 

Jiang J, Zhao PL, Sigua LH, Chan A, Schönbrunn E, Qi J, et al. 1, 4-Dihydropyridinebutyrolactone-derived ring-opened ester and amide analogs targeting BET bromodomains. Arch Pharm (Weinh). 2022;355:2200288.

Article  CAS  Google Scholar 

Jiang J, Liang T, Solberg J, Chan A, Kalra P, Shi R, et al. Macrocyclic dihydropyridine analogs as pan-BET BD2-preferred inhibitors. Eur J Med Chem. 2025;290:117504.

Article  CAS  PubMed  Google Scholar 

Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Larochelle S, Pandur J, Fisher RP, Salz HK, Suter B. Cdk7 is essential for mitosis and for in vivo Cdk-activating kinase activity. Genes Dev. 1998;12:370–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ganuza M, Sáiz-Ladera C, Canamero M, Gomez G, Schneider R, Blasco MA, et al. Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion. EMBO J. 2012;31:2498–510.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Diab S, Yu M, Wang S. CDK7 inhibitors in cancer therapy: the sweet smell of success?. J Med Chem. 2020;63:7458–74.

Article  CAS  PubMed  Google Scholar 

Schachter MM, Fisher RP. The CDK-activating kinase Cdk7: taking yes for an answer. Cell Cycle. 2013;12:3239–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang M, Wang T, Zhang X, Wu X, Jiang S. Cyclin-dependent kinase 7 inhibitors in cancer therapy. Future Med Chem. 2020;12:813–33.

Article  PubMed  Google Scholar 

Liang H, Du J, Elhassan RM, Hou X, Fang H. Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy. Expert Opin Investig Drugs. 2021;30:61–76.

Article  CAS  PubMed  Google Scholar